# Coya Therapeutics, Inc. (COYA)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001835022 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001835022))
- Full page: https://inspectstocks.com/stocks/coya
- Data as of: price 2026-09-29; newest filing used 2026-08-11; latest fiscal period ended 2026-06-30

## Grade

**F-** on the balance-sheet rubric used for lenders, 0 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$21.7M |  |
| Earnings growing overall | failed | -$21.7M | -$13M |
| Earnings growing recently | failed | -$21.7M | -$21.2M |
| Earns well on its assets | failed | -45.8% |  |
| Book value per share growing | not answerable | $2.57 | -$3.24 |

Business quality (the + / − mark): 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -270.2% |  |
| Healthy profit margin | failed | -270.2% |  |
| Strong operating margin | failed | -288.7% |  |
| Good return on equity | failed | -50.4% |  |
| Debt under control | passed | 0.30 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $8M |
| Net income, trailing twelve months | -$21.7M |
| Net margin | -270.2% |
| Operating margin | -288.7% |
| Return on equity | -50.4% |
| Debt to equity | 0.30 |
| Diluted EPS, trailing twelve months | -$1.07 |
| Share price | $5.05 |
| Market value | $118.3M |
| Price / sales | 14.8x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/coya)
- [Financial statements](https://inspectstocks.com/stocks/coya/financials)
- [Competitors](https://inspectstocks.com/stocks/coya/peers)
- [Earnings](https://inspectstocks.com/stocks/coya/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.